Biotech firm secures £5 million to scale innovations
A biotechnology company is set to accelerate the production and global reach of its groundbreaking cell-analysis technology following a successful £5 million funding round.
Cytomos, based in Edinburgh, will use the investment - led by Archangels and supported by Old College Capital, Scottish Enterprise and British Business Bank - to drive sales of its flagship product, Celledonia™.
Built on its AuraCyt platform, Celledonia™ is a benchtop analyser designed to transform biological drug discovery and manufacturing by enabling faster, more cost-effective cell analysis. The AuraCyt platform provides real-time insights into cell parameters to accelerate drug development by up to six months while reducing costs. Its innovative approach to cell analysis meets a critical need for scalable, low-cost solutions in the biopharma sector.
Operating from new premises in Roslin, Cytomos employs 21 staff and plans to expand further as it scales operations and enters the North American market. The company has trials planned with global partners, including a top 10 pharma firm, and is exploring co-development opportunities with technology leaders.
David Rigterink, chief executive officer at Cytomos, said: “Successfully raising £5 million within a difficult market has been a huge boost for the business.
“The result is testament to the team’s hard work in delivering our first commercial product with international early adopters. Cytomos now has the right building blocks in place to scale quickly, establish a foothold in the US, and continue developing our single cell analysis technology to support advancements in biological drug development and manufacturing automation.”
Sarah Hardy, director and head of new investments at Archangels, added: “Cytomos has gone from strength to strength, achieving commercialisation earlier this year marks a critical inflection point for the business.
“With new premises secured and a robust plan to derisk the supply chain, we’re looking forward to helping David and the team scale their operations and secure access to new markets.”
Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →
Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.
Enjoy the read? Get Bdaily delivered.
Sign up to receive our popular morning National email for free.
The rise of an alternative investor model
Bots don't beat personal business coaching
From COVID-19 to the Middle East crisis
How to build credibility in B2B marketing
Is your business ready for the trade union change?
Government 'must take its foot off businesses' throats'
Upskilling key to civil engineering's future
Why apprenticeships are becoming a strategic asset
Business growth requires the right environment
OpenAI decision a wake-up call for our tech plans
Understanding the new Employment Rights Act
Why global conflict is a cyber risk for UK SMEs